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Abstract
Both locally advanced adenocarcinoma of the stom-
ach and gastro-esophageal junction are associated with
poor prognosis due to the lack of effective treatment.
Recently multimodal treatment consisting of neoadju-
vant chemotherapy in combination with radiotherapy
is  reported  to  improve  survival  when  compared  to
surgery alone. Neoadjuvant therapy in these locally ad-
vanced tumors allows for early tumor responses and
the extent of tumor regression that can be achieved is
considered  a  significant  prognostic  factor.  This,  in
turn, increases the resectability of these tumors. also
due to the high frequency of lymph node metastasis,
patients with locally advanced adenocarcinoma should
undergo a d2 lymphadenectomy.Postoperative chemo  -
radiation  and  perioperative  chemotherapy  have  been
studied in gastric adenocarcinomas and showed a sur-
vival benefit. However, the surgical techniques used in
these trials are no longer considered to be standard by
today’s surgical practice. In addition, there are no stan-
dard recommendations for adjuvant chemotherapy or
chemoradiation after R0 resection and adequate lymph
node dissection.
INTRoducTIoN
Radiation  therapy  for  adenocarcinoma  of  the  upper
gastrointestinal tract is reliant on both tumor location
and stage. In Germany, distal esophageal adenocarci-
noma of the esophagus is more common than squa-
mous  cell  carcinoma  of  the  distal  esophagus  and
shows an over-all higher incidence. also, the diagnosis
of adenocarcinoma of the distal esophagus (Barrett's
carcinoma) usually occurs in earlier stages compared
to squamous cell carcinoma and therefore has an over-
all better long-term outcome. although the treatment
of  advanced  esophageal  and  gastric  cancer  includes
neoadjuvant chemoradiation, neoadjuvant chemother-
apy is the treatment of choice. The utilization of ra-
diotherapy in the treatment of advanced gastric and
lower esophageal cancer is not only underrepresented,
but also less investigated in prospective studies. In this
review we are providing insights into the role of radia-
tion  therapy  of  adenocarcinomas  of  the  upper  gas-
trointestinal tract.
NEoadJuvaNT THERaPy of GaSTRo-
ESoPHaGEal JuNcTIoN
adenocarcinomas of the distal esophagus have a high
propensity of lymph node metastasis and transcending
mucosal spread of disease. These are the main factors
limiting  the  curative  potential  of  surgical  treatment.
Therefore,  the  use  of  multimodal  therapeutic  ap-
proaches in locally advanced Barrett's carcinoma (T3
and  T4  stage)  and  in  patients  with  extensive  lymph
node  metastasis  is  indicated.  The  current  data  for
postoperative  radiation  therapy  or  chemotherapy  do
not provide convincing evidence for either treatment. 
In recent years, the efficacy of neoadjuvant therapy
approaches in the treatment of esophagus tumors (e.g.
adenocarcinoma  and  squamous  cell  carcinomas)  has
been  investigated  in  various  prospective  randomized
studies and metaanalyses [1-4]. Gebski et al. summa-
rize the available randomized trials from 1982 to 2006
for neoadjuvant chemotherapy or chemoradiation [5].
In  the  included  trials,  the  applied  radiation  doses
ranged  from  20-50  Gy,  whereas  the  majority  of
chemotherapeutic  trials  utilized  cisplatin  and  5-fluo-
rouracil  administered  either  concurrently  or  sequen-
tially in combination with radiotherapy. The chemora-
diation of both adeno- and squamous cell carcinomas
demonstrated a significant improvement (13%) in the
2-year overall survival rates as compared to a single
modality of surgical resection (hazard ratio 0.81, p =
0.002).
Interestingly,  a  significant  survival  advantage  was
demonstrated  for  adenocarcinomas  of  the  distal
esophagus  for  both  neoadjuvant  chemotherapy  and
neoadjuvant  chemoradiation.  However,  in  squamous
cell carcinoma of the esophagus the survival advan-
tage was only observed in the neoadjuvant concurrent
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therapy is directly correlated to the extent of the pri-
mary tumor size, whereas the treatment of locally ad-
vanced tumors with neoadjuvants revealed higher sur-
vival rates. 
a  recent  metaanalysis  reported  an  improved  sur-
vival rate of 7% after 2 years following administration
of neoadjuvant chemotherapy for esophageal cancer
compared  to  a  organ  resection  alone  (HR  0.9,  p  =
0.05) [5]. However, this significant improvement could
only be statistically demonstrated for adenocarcinomas
of the esophagus (HR 0.78), but not for patients with
squamous cell carcinomas (HR 0.88, p = 0.12).
The role of neoadjuvant radiotherapy was also inves-
tigated in a metaanalysis of 1147 patients [5 random-
ized controlled studies of potentially resectable esopha  -
geal cancer, mostly squamous cell carcinomas] [6]. after
a median follow-up of 9 years, no significant survival
benefit for neoadjuvant radiotherapy was noted. There-
fore, at this time neoadjuvant radiotherapy cannot be
recommended as a standard treatment option.
With regard to most studies regarding multimodal
treatment  of  gastro-esophageal  junction  cancer  or
squamous cell carcinoma of the esophagus, it appears
to be a major disadvantage that both tumor entities
were mostly treated and analyzed in one group. There-
fore, interpretations of the metaanalysis regarding tu-
mors of the upper gastrointestinal tract are very diffi-
cult to interpret. 
although one randomized study by Walsh et al. de-
scribed  an  advantage  for  the  combined  radio-
chemotherapy  of  adenocarcinoma,  many  discrepan-
cies  were  reported  by  this  study  [7].  Moreover,  the
study was limited to a relatively small number of pa-
tients and a disproportionately poor survival rate in
the surgical treatment group according to the litera-
ture. Nevertheless, one big advantage of this study is
that only adenocarcinomas of the upper gastrointesti-
nal tract were included.
another important study is the cross study from
van der Gast, presented at the aSco 2010 meeting
[51]. In this study, 363 patients with advanced stages
of esophageal cancer, high percentage of adenocarci-
noma (74%) and lymph node involvement were ran-
domized  to  surgery  alone  or  radiotherapy  and
chemotherapy  with  carboplatin  /  paclitaxel  prior  to
surgery. In this study the patients benefited significant-
ly from the neoadjuvant therapy in terms of a pro-
longed survival rate. Interestingly, the effect was more
pronounced in the small group of squamous cell carci-
nomas,  while  the  larger  group  of  adenocarcinomas
showed only a trend. There was no increase of periop-
erative mortality in the neoadjuvant treatment arm.
Neoadjuvant radiotherapy is poorly evaluated on a
phase III level. one randomized study from china in-
vestigated the value of preoperative radiotherapy and
included 370 patients receiving 40 Gy / 2 Gy fractions
with linear arc or co 60 [19]. an analysis of the study
population showed a significant increase for the sur-
vival rate after 5 years from 20% to 30 % (p=0.009)
when treated with radiotherapy. The local tumor con-
trol also increased form 48% to 61%. 
a  prospective  randomized  multicenter  study  by
Stahl et al. compared adenocarcinomas of the gastro-
esophageal junction after neoadjuvant chemoradiation
or neoadjuvant chemotherapy with regard to the sur-
vival  of  patients  after  tumor  resection  [8].  Patients
with locally advanced (uT3-4NXM0) adenocarcinoma
of the lower esophagus or gastric cardia were random-
ly allocated to one of two treatment groups: Induction
chemotherapy (15 weeks) followed by surgery (arm a);
or chemotherapy (12 weeks) followed by chemo-radio-
therapy (3 weeks) followed by surgery (arm B). Prima-
ry outcome was overall survival time. a total of 354
patients were needed to detect a 10% increase in 3-
year survival from 25% to 35% by addition of radia-
tion therapy. The study was prematurely closed due to
low  accrual.  The  median  observation  time  was  46
months.  a  total  of  126  patients  were  randomly  as-
signed and 119 eligible patients were evaluated. The
number of patients undergoing complete tumor resec-
tion  was  not  different  between  treatment  groups
(69.5% vs 71.5%). Patients in arm B had a significant
higher probability of showing pathologic complete re-
sponse (15.6% vs 2.0%) or tumor-free lymph nodes
(64.4% vs 37.7%) at resection. Preoperative radiation
therapy improved 3-year survival rate from 27.7% to
47.4% (log-rank p = 0.07, hazard ratio adjusted for
randomization strata variables 0.67, 95% cI, 0.41 to
1.07). Postoperative mortality was not significantly in-
creased  in  the  chemo-radiotherapy  group  (10.2%  vs
3.8%; p = 0.26). although the study was closed early
and  statistical  significance  was  not  achieved,  results
point to a survival advantage for preoperative chemo-
radiotherapy compared with preoperative chemothera-
py in adenocarcinomas of the esophago-gastric junc-
tion.
an overview of the randomized studies comparing
neoadjuvant radio-chemotherapy versus surgery alone
is shown in Table 1.
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Table 1. Survival rate after neoadjuvant radio-chemotherapy for locally advanced adenocarcinoma.
Study adeno-carcinoma Survival RTX Survival Surgery p-value
n (%)
Walsh et al. 1996 [7] 113 (100%) 32% (3 y) 6% (3 y) 0.01
urba et al. 2001 [43] 75 (75%) 30% (3 y) 16% (3 y) 0.15
Burmeister et al. 2005 [44] 158 (62%) 28% (3 y) 30% (3 y) 0.81
Tepper et al. 2008 [45] 42 (75%) 39% (5 y) 16% (5 y) 0.002
Stahl et al. 2009 [8] 119 (100%) 47.7% (3 y) 27.4% 0.07
(cHX, 3 y)
RTX = radio-chemotherapy, cHX = chemotherapy, y = years
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domized phase III trials due to the low patient recruit-
ment.
finally, it should be noted that the MRc trial, a trial
investigating the role of perioperative chemotherapy
for  esophageal  cancer,  showed  a  significant  survival
benefit for adenocarcinoma of the distal esophagus as
compared to squamous cell carcinoma [9]. The new S3
guideline  in  Germany  recommends  a  neoadjuvant
chemo- or radio-chemotherapy for T2 tumors. 
NEoadJuvaNT cHEMoTHERaPy foR GaSTRIc
adENocaRcINoMa
a frequently cited multicenter trial (MaGIc trial) in-
vestigated  the  efficacy  of  a  pre-  and  postoperative
chemotherapy. This regimen consisted of three cycles
of epirubicin, cisplatin and 5-fu with the endpoints
of determining tumor control and survival rate in all
patients  with  gastric  adenocarcinoma  (n  =  372  pa-
tients)  and  of  patients  with  tumors  in  the  gastric-
esophageal junction (n = 131 patients). The combined
arm showed a benefit especially for the adenocarcino-
ma of the distal esophagus. for patients with tumors
of the gastric esophageal junction this could not be
demonstrated since it would have been an unplanned
subgroup analysis [10].
unfortunately,  only  42%  of  all  patients  in  the
chemotherapy arm finished the study according to the
protocol. 34% of all patients finished their treatment
after preoperative chemotherapy and surgery without
receiving  postoperative  chemotherapy.  The  authors
described a 5-year survival rate of 36.3% compared to
23% in favour of the chemotherapy group. Because
more than half of all patients did not have a postoper-
ative chemotherapy, the observed effect is probably an
effect  of  the  preoperative  chemotherapy.  This  work
promoted  the  use  of  neoadjuvant  chemotherapy  in
gastric cancer (Table 2).
a comparable trial was a french multicenter study
[fNlcc  accord07-ffcd  9703]  [11].  In  this  study,
75% of all patients had adenocarcinoma of the distal
esophagus or of the gastro-esophageal junction. The
R0  resection  rate  after  neoadjuvant  therapy,  which
consisted of 2-3 cycles of cisplatin and 5-fu, was sig-
nificantly  improved  compared  to  surgical  resection
alone (84% vs 73%, p = 0.04). The authors of this
study  observed  a  downsizing  for  lower  tumor  and
nodal stages in the mutimodal treatment arm. further-
more,  in  the  multimodal  treatment  arm  1-4  course
chemotherapy was planned as in the MaGIc trial, but
only  50%  of  their  patients  were  able  to  get  the
chemotherapy.  The  difference  in  the  5  year  disease
free survival rate was 13% (34% vs 21%, p = 0.0033)
and the 5 year overall survival rate was 38% vs 24% (p
= 0.021) in favour of the neoadjuvant therapy.
RolE of adJuvaNT cHEMoTHERaPy foR THE
GaSTRIc adENocaRcINoMa
S1 compared the two arms of a Japanese trial with 530
patients treated with surgery alone and 529 patients
treated  with  postoperative  chemotherapy  using
floropyrimidin and found no difference between the
treatment arms [12]. almost all patients received a d2
lymphadenectomy. S1 was able to reduce the risk for
peritoneal and lymphogenic recurrences. analysis for
the 3-year survival rate revealed that adjuvant therapy
was significantly associated with longer survival com-
pared to surgery alone (p = 0.003). other metaanaly-
ses for randomized studies which analyzed postopera-
tive  chemotherapy  versus  surgery  alone  revealed  a
marginal survival benefit for the adjuvant therapy [13-
17]. Nevertheless, these results could not be repeated
outside of Japan and may be restricted to the asian re-
gion. currently, no study exists in the Western hemi-
sphere analyzing a sufficient number of patients re-
vealing a significant benefit with adjuvant chemothera-
py [18].
NEoadJuvaNT RadIoTHERaPy foR
adENocaRcINoMa
a meta-analysis performed in 2007, revealed a slight
but  significant  survival  benefit  for  patients  treated
with  preoperative  radiotherapy  [20].  However,  the
study  population  was  heterogeneous  including  intra-
operative  radiotherapy  patients.  The  available  data
show that there might be a benefit from this treatment
protocol, though the data are not valid.
adJuvaNT RadIoTHERaPy foR GaSTRIc
adENocaRcINoMa
until now, there were no phase III trials investigating
the  role  of  neoadjuvant  radio-chemotherapy  in  the
therapy  of  gastric  cancer.  However,  recently  a  large
american trial investigated the role of adjuvant radio-
chemotherapy in gastric cancer [21]. In this study, pa-
tients were randomized after curative surgery to either
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Table 2. Survival rate after neoadjuvant chemotherapy for advanced adenocarcinoma.
Study adeno-carcinoma  Survival cHX + Surgery Survival Surgery p- value
n  (%)
MRc, 2002 [9] 528 (66 %) 32% 25% 0.02
(3 y) (3 y)
MaGIc, 2006 [10] 503 (100 % dist.  36.3% 23% 0.009
esophagus and stomach) (5 y) (5 y)
ffcd , 2007 [11] 226 (100 % dist.  38% 24% 0.021
esophagus and stomach) (5 y) (5 y)
cHX = chemotherapy, y = years
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Gy and simultaneous application of 5-fu plus leucov-
erin (2 cycles) or to no adjuvant treatment at all. after
three years this study demonstrates a survival benefit
of 9 % for patients treated with radio-chemotherapy
(50% vs 41%, p = 0.005). one disadvantage of this
study  is  the  inadequate  number  of  resected  lymph
nodes, since only 10% of all patients received a d2
lymphadenectomy. Therefore, the conclusion of this
study is not applicable to patients treated with stan-
dard resection techniques. The inadequate surgery rep-
resents the major problem of this study, since 54% of
all patients did not even undergo a d1 lymph node re-
section [22, 23].
Efforts to intensify the above mentioned Mcdon-
ald study [RToG 0114] have had no positive effect for
the  patients  [24].  In  this  study,  two  treatment  arms
were  analyzed:  Induction  chemotherapy  followed  by
simultaneous radiation compared to cisplatin and pa-
clitaxel (Pc) or cisplatin, paclitaxel and 5-fu (Pcf) in
the other arm. 59% of all patients treated in the Pcf
arm showed grade III side effects according to cTc
(common toxicity criteria). Therefore, this study was
stopped.  furthermore,  the  Pc  arm  showed  inferior
disease-free survival when compared to the Mcdonald
study [24]. 
another important study is by Kim et al [46] from
Korea, confirming the SWoG results for d2 lymph
node resection. Their observational study suggested a
clinical benefit resulting from adjuvant postoperative
chemoradiation in a series of 544 patients with adeno-
carcinoma of the stomach after gastric resection in-
cluding d2 node dissection.
a  successful  intensification  of  the  chemotherapy
was  achieved  by  Kollmannsberger  et  al.  [47].  This
phase  II  study  included  weekly  paclitaxel,  24-hour
continuous infusion of 5-fluorouracil, folinic acid and
cisplatin  in  patients  with  advanced  gastric  cancer.
forty-five chemotherapy-naive patients (28 male and
17  female)  with  a  median  age  of  60  (range,  35–74)
years were enrolled. 5-fu 2 g/m2 was given weekly
over 24 h i.v. preceded by folinic acid 500 mg/m2 as a
2 h infusion. Paclitaxel, 175 mg/m2, was administered
as a 3 h-infusion on days 1 and 22 and cisplatin 50
mg/m2 as 1 h infusion on days 8 and 29. Six weeks of
therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks
rest  were  considered  as  one  cycle.  a  median  of  3
(range 1–4) cycles were administered to 45 patients as-
sessable for response, survival and toxicity. five pa-
tients (11%) obtained a complete remission and 18 pa-
tients (40%) a partial remission (oRR 51%; 95% cl:
35.8–66.3%).  Responses  were  achieved  in  the  liver,
lymph nodes, lungs and at the site of the primary tu-
mor. Nine patients (20%) presented with stable dis-
ease. Thirteen patients (29%) were considered to have
failed treatment, 8 patients (18%) due to progressive
disease and 5 patients (11%) who did not receive one
complete cycle of therapy due to acute non-haemato-
logic toxicity. The median progression-free and overall
survival times were 9 (range 1–36+) months and 14
(range 2–36+) months, respectively.
It has to be noted that the cRITIcS study (chemo
Radiotherapy after Induction chemo Therapy in can-
cer of the Stomach) from Holland is still enrolling pa-
tients. at the Netherlands cancer Institute, a Phase I-
II study with daily adjuvant cisplatin and capecitabine
based  chemo-radiotherapy  has  just  been  finished  in
over  120  patients  with  resected  gastric  cancer.  This
study demonstrated that intensive postoperative con-
current  chemo-radiotherapy  is  feasible.  currently,  a
weekly cisplatin regime is evaluated as an alternative to
the daily schedule. The cRITIcS study is a random-
ized phase III trial in which all patients will receive 3
courses  of  Ecc  (epirubicin,  cisplatin,  capecitabine)
chemotherapy and then have a d1+ gastric resection.
after  surgery,  patients  will  either  receive  another  3
courses of Ecc chemotherapy or chemo-radiotherapy
(45 Gy in 25 fractions, with daily/weekly cisplatin and
daily capecitabine). In order to detect a 10% benefit in
overall survival, 788 patients will have to be included.
Endpoints of this study are overall and disease-free
survival, toxicity and quality of life. furthermore, tis-
sue banking and analysis (genomics, proteomics) will
be part of the study. Quality assurance both in radio-
therapy and surgery (Maruyama index) will be obliga-
tory (http://www.dccg.nl/trials/critics).
RESPoNSE EvaluaTIoN aNd RESPoNSE
PREdIcTIoN
all prospective studies have shown positive tumor re-
sponse to neoadjuvant therapy, which is considered as
an independent prognostic factor. These patients, the
so-called responders, have a significantly better prog-
nosis  than  non-responders  [25-27].  The  selection  of
non-responders may play an important role in avoid-
ing  unnecessary  costs  and  unnecessary  toxic  treat-
ments with side effects. at the moment, there are no
studies revealing a benefit of immediate surgical inter-
vention improving the prognosis of non-responders.
due to a lack of randomized studies there is the hy-
pothesis  that  treatment  options  should  be  selected
based on response rates detected by PET-cT. 
for gastric cancer tumor specific factors like p53,
microsatellite instability, aberrant dNa hypermethyla-
tion  and  single  nucleotide  polymorphisms  (SNP),
which are related to chemo  therapy response, are not
known.  Such  tumor  specific  factors  should  be
prospectively evaluated for response prediction. HER-
2/neu (c-erbB-2, HER2) gene amplification and pro-
tein  overexpression  have  been  associated  with  poor
prognosis in several solid tumors, including breast and
gastric  cancer.  Its  incidence  and  significance  in
esophageal adenocarcinoma is unknown. [28-31, 54]. 
clINIcal EvaluaTIoN of TREaTMENT
RESPoNSE
for  the  detection  of  tumor  regression  induced  by
neoadjuvant  therapy,  endoscopy,  biopsy  and  en-
dosonography  are  image-guided  procedures,  which
are currently available. yet, the interpretations of the
diagnostics regarding therapeutic response or non-re-
sponse are difficult [33, 34]. a decision guideline is
now available in the recently updated German S 3 rec-
ommendations. The major question remains the deci-
sion between surgery or radio-chemotherapy after re-
staging. for squamous cell carcinoma of the esopha-
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ed that responders were not associated with survival
benefit after surgery compared to radio-chemotherapy
alone. Nevertheless, these results could not be con-
firmed for adenocarcinoma of the gastric-esophageal
junction.
It remains controversial if surgical resection after
neoadjuvant  therapy  is  mandatory,  while  a  benefit
could clearly be demonstrated for patients with tumor
progression  and  development  of  metastatic  disease
and inoperability [33]. a further disadvantage of the
clinical  response  evaluation  is  the  time  interval  for
surgery. In most studies, a time interval of 4-6 weeks
is  needed  prior  to  surgery  [32].  In  patients  without
neoadjuvant radiation, this time span may be shorter.
usually, the blood count should be within normal lim-
its after 3 weeks.
HISToPaTHoloGIcal RESPoNSE
after neoadjuvant therapy followed by tumor resec-
tion, the histopathological regression grade should be
evaluated (fig. 3), since a substantial amount of data
has  suggested  that  pathologic  tumor  regression  fol-
lowing neoadjuvant therapy is an important predictor
of  local  recurrence  and  long-term  survival  in
esophageal cancer [35]. In this context, various tumor
regression grading systems were established, starting
with Mandard et al. in 1994 [51]. In most of the stud-
ies patients with complete tumor regression have a sig-
nificantly better survival probability. In addition, pa-
tients with less than 10 % vital residual tumor cells
(vRTc)  (so-called  major  histopathological  response)
exhibited a significantly better 3-year survival rate after
neoadjuvant  radio-chemotherapy.  furthermore,  the
lymph node status (ypN0 vs ypN1) represented a sig-
nificant prognostic parameter. Summarized, a regres-
sion classification based on grade of vRTc and lymph
node status led to improved survival prediction [52,
53]. With regard to gastric cancer, Becker et al. de-
scribed  a  similar  system  of  tumor  regression  [26],
which applies three grades: Grade 1, complete (0% vi-
tal tumor cells) or subtotal tumor regression (< 10 %
vital  tumor  cells),  grade  2,  partial  tumor  regression
(10%- 50% vital tumor cells) and grade 3, minimal or
no tumor regression (> 50% vital tumor cells) [26]. a
correlation between tumor regression grade and sur-
vival was also observed in this study. 
Several investigations showed the prognostic value
of tumor response in accordance to the survival date.
Patients with complete tumor regression revealed the
highest  benefit  for  multimodal  treatment  approach
[36]. Perhaps this subgroup is the best group for fu-
ture adjuvant treatment modalities. 
METaBolIc RESPoNSE
fdG-PET  (fluor-18-deoxyglucose-positronemission-
tomography)  has  proven  to  be  a  highly  sensitive
method  to  detect  response  after  2  weeks  following
chemotherapy [36-38]. The measurement of the glu-
cose uptake of the primary tumor after induction of
neoadjuvant  chemotherapy  compared  with  the  stan-
dard  uptake  values  before  chemotherapy  represents
differentely differently if the patient was a responder
or not.
The MuNIcoN, a phase II study, showed that an
early interruption of the treatment is not a disadvan-
tage for metabolic non responders [36, 39]. However,
these data could not be confirmed by any Phase III
study. Neoadjuvant chemotherapy, based on patients'
response, would be a step forward for an individual-
ized and selective approach of neoadjuvant treatment
modalities. It is also the subject of ongoing and future
clinical trials [36]. for gastric cancer an association be-
tween metabolic, clinical and histopathology responses
was observed. although in gastric cancer the tumor
biology and prognosis for responders and non respon-
ders is different, the current available data are not suf-
ficient to perform a clinical trial [24, 40]. Nevertheless
there  are  new  innovative  individualized  therapy  ap-
proaches  planned,  especially  for  patients  with  meta-
bolic non response [4].
THE RolE of TEcHNoloGy aNd SIdE
EffEcTS of RadIoTHERaPy
In phase II and III studies, the treatment volume in-
cluded the primary tumor with a lateral safety margin
of 2 cm to the tumor and a cranial caudal safety mar-
gin of 3-5 cm. The involvement of suspicious lymph
nodes  (paraesophageal,  mediastinal,  coeliacal,  and  in
certain  circumstances  supraclavicular)  is  obligatory
(figs. 1-3). 
Generally, the preoperative radiation dosage ranged
between 36 and 45 Gy with a fractionation dose of
1.8-2.0 Gy per day. The entire treatment period is be-
tween  4  and  5  weeks.  for  treatment  planning,  lung
sparing techniques as anterior posterior / posterior an-
terior or opposing fields should be used. Modern cT
planning helps to reduce the lung mean dosage. Inter-
esting is an investigation on 110 patients with preoper-
ative  radio-chemotherapy.  The  authors  showed  that
the postoperative complication rate correlates with the
mean  lung  dose  [42].  In  this  study  the  patients  re-
ceived  41-50  Gy.  for  chemotherapy  the  patients  re-
ceived 5-fu, taxane and cisplatin. The irradiated lung
volume had a positive correlation with the incidence
of  lung  complications.  at  the  moment,  we  recom-
mend  to  use  ddP  (cis-diaminodichloroplatinum  or
cisplatin) and 5 fu as a chemotherapeutic regiment
outside from studies.
The most common acute side effects during radio-
chemotherapy is dysphagia. The major reason is the
development of a mucositis of the esophageal mucous
membrane. also late side effect on the heart and lung
can occur. The dosage to the spinal cord is not critical
for the different neoadjuvant concepts.
The  side  effects  on  chemotherapy are different
from the side effects of radiotherapy.
Severe  infections  due  to  the  vulnerability  of  the
esophageal mucous membrane can occur. 
according to some authors, a contraindication for a
neoadjuvant radio-chemotherapy is the possible tumor
infiltration of the tracheobronchial system. Tracheo-
bronchial fistula can occur inducing severe complica-
tions.  yet,  this  is  discussed  controversially  and  goes
back to a time when no stents were available. 
EuRoPEaN JouRNal of MEdIcal RESEaRcH June 21, 2011 269
5) Matuschek/Bölke_Umbruchvorlage  03.06.11  17:20  Seite 269EuRoPEaN JouRNal of MEdIcal RESEaRcH 270 June 21, 2011
Fig. 1. PET-cT with a clear circular wall thickening of the distal esophagus and increased glucose uptake (Suv max. 12,4).
Fig. 2. Treatment plan and dose
distribution for 3 d conformal
radiation therapy.
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Fig. 3. Gastric adenocarcinomas after neoadjuvant chemo  therapy showing no tumor regression (a) or major regression with
only few scattered vital residual tumor cells (B). adenocarcinoma of the gastro-esophageal junction exhibiting major regression
after radio-chemotherapy (c, d).
Fig. 2. continued.
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domized trials involving patients with squamous cell
carcinoma  of  the  esophagus  showed  an  increase  in
toxicity  to  preoperative  radiotherapy  and  chemo-ra-
diotherapy resulting in an increased mortality rate. a
recently  published  trial  comparing  neoadjuvant
chemotherapy  (Pfl  arm)  with  neoadjuvant  radio-
chemotherapy  (PlG  with  simultaneous  30  Gy  and
cisplatin etoposid) revealed no elevated mortality rate
in  the radio-chemotherapy arm (5 from 49 patients
and 2 from 52 patients, p = 0.26). length of hospital
stay, intubation period, and treatment on the intensive
care unit did not differ between groups [8]. Radiother-
apy does not seem to be a significant risk factor. an
analysis of all published randomized data shows that
preoperative radio-chemotherapy in adenocarcinomas
of the esophagus does not increase the postoperative
mortality rate. 
coNcluSIoN
a  meta-analysis  in  the  treatment  of  advanced
esophageal cancer shows a survival benefit for patients
treated  with  neoadjuvant  chemotherapy  or  radio-
chemotherapy. However, the rate of histological com-
plete remission is higher after chemoradiation than af-
ter  chemotherapy  alone.  after  neoadjuvant  therapy
esophageal cancer patients with less than 10% viable
residual  tumor  cells  (high  pcR  rate)  have  a  better
chance of survival than patients without a significant
tumor regression.
In  gastric  adenocarcinoma,  radiotherapy  has  not
been adequately evaluated. after a sufficient d2 lymph
node resection there is no indication for adjuvant ra-
dio-chemotherapy.  However,  after  inadequate  lymph
node  resection,  adjuvant  radio-chemotherapy  should
be  considered.  The  usual  postoperative  radio-
chemotherapy in the uSa should not be completely
transferred to European patients due to different radi-
cal surgery techniques. In experienced centers, preop-
erative chemoradiation is compatible with subsequent
surgery  and  does  not  constitute  a  perioperative  risk
factor. future therapies will be defined by clinical re-
sponse and molecular factors and will allow for better
individual therapy.
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